Keros Therapeutics (KROS) Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Keros+Therapeutics+%28KROS%29+Announces+U.S.+FDA+Fast+Track+Designation+for+KER-050+in+Lower-Risk+Myelodysplastic+Syndromes/22929699.html for the full story.

Leave a Reply

Your email address will not be published. Required fields are marked *